Alfresa Holdings Corporation (JP:2784)
:2784
Want to see JP:2784 full AI Analyst Report?
Top Page
Alfresa Holdings
(2784)
Select Model
Select Model
Rating:78Outperform
Price Target:
¥2,935.00
▲(16.33% Upside)
Action:ReiteratedDate:11/28/25
Alfresa Holdings scores well due to its strong financial performance and technical indicators. The company's robust balance sheet and consistent revenue growth provide a solid foundation, while technical analysis indicates strong bullish momentum. The valuation is reasonable, with a fair P/E ratio and attractive dividend yield. However, potential overbought technical indicators suggest caution for short-term investors.
Positive Factors
Strong balance sheet
Extremely low leverage and a solid equity ratio give Alfresa durable financial flexibility to fund working capital and logistics needs typical of pharmaceutical distribution. This reduces solvency risk and supports capital allocation for operations, M&A, or infrastructure over the medium term.
Negative Factors
Razor-thin profitability
Very low operating and net margins leave limited buffer against cost inflation, reimbursement or procurement pricing shifts. Sustained thin profitability constrains reinvestment in distribution infrastructure and limits ability to improve returns to shareholders over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Extremely low leverage and a solid equity ratio give Alfresa durable financial flexibility to fund working capital and logistics needs typical of pharmaceutical distribution. This reduces solvency risk and supports capital allocation for operations, M&A, or infrastructure over the medium term.
Read all positive factors
Alfresa Holdings (2784) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥455.89B
Dividend Yield2.69%
Average Volume (3M)354.02K
Price to Earnings (P/E)5.4
Beta (1Y)0.67
Revenue Growth4.11%
EPS Growth0.40%
CountryJP
Employees12,517
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)112.56
Shares Outstanding191,300,000
10 Day Avg. Volume331,350
30 Day Avg. Volume354,016
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)0.81
Price to Sales (P/S)0.13
P/FCF Ratio-36.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,400.00Price Target Upside-4.88% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)163.55
Revenue Forecast (FY)¥3.15T
Alfresa Holdings Business Overview & Revenue Model
Company Description
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ...
How the Company Makes Money
Alfresa Holdings primarily makes money by acting as an intermediary in the healthcare supply chain, purchasing pharmaceuticals and other healthcare products from manufacturers and selling them to downstream customers such as hospitals, clinics, an...
Alfresa Holdings Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
85
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.00T | 2.96T | 2.86T | 2.70T | 2.59T | 2.61T |
| Gross Profit | 215.35B | 202.71B | 196.36B | 182.26B | 178.31B | 174.68B |
| EBITDA | 53.20B | 53.20B | 51.98B | 43.45B | 41.92B | 39.80B |
| Net Income | 27.96B | 27.39B | 29.56B | 25.79B | 32.18B | 24.50B |
Balance Sheet | ||||||
| Total Assets | 1.48T | 1.44T | 1.45T | 1.34T | 1.30T | 1.32T |
| Cash, Cash Equivalents and Short-Term Investments | 180.61B | 177.09B | 213.76B | 160.12B | 180.44B | 170.34B |
| Total Debt | 30.60B | 35.55B | 34.94B | 3.85B | 5.04B | 5.58B |
| Total Liabilities | 999.83B | 957.63B | 967.76B | 851.51B | 832.15B | 826.69B |
| Stockholders Equity | 478.32B | 481.79B | 479.60B | 488.09B | 471.59B | 489.74B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -10.87B | 73.64B | -9.63B | 21.54B | -36.24B |
| Operating Cash Flow | 0.00 | 5.64B | 86.38B | 13.09B | 36.55B | -21.19B |
| Investing Cash Flow | 0.00 | -24.92B | -14.22B | -20.54B | 2.30B | -4.73B |
| Financing Cash Flow | 0.00 | -23.53B | -19.70B | -12.92B | -29.15B | -14.47B |
Alfresa Holdings Technical Analysis
Negative
2523.00
Price Trends
2492.88
Negative
2454.88
Negative
2285.17
Positive
Market Momentum
-1.67
Positive
41.61
Neutral
9.81
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2784, the sentiment is Negative. The current price of 2523 is above the 20-day moving average (MA) of 2496.88, above the 50-day MA of 2492.88, and above the 200-day MA of 2285.17, indicating a neutral trend. The MACD of -1.67 indicates Positive momentum. The RSI at 41.61 is Neutral, neither overbought nor oversold. The STOCH value of 9.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2784.
Alfresa Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥455.89B | 5.40 | 6.92% | 2.69% | 4.11% | 0.40% | |
69 Neutral | ¥441.50B | 14.05 | 11.37% | 3.04% | 5.64% | 3.22% | |
69 Neutral | ¥317.32B | 7.24 | 8.60% | 1.60% | 1.50% | 11.07% | |
68 Neutral | ¥504.06B | 9.27 | 6.39% | 2.27% | 3.42% | -15.06% | |
67 Neutral | ¥347.08B | 16.82 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥598.41B | 14.44 | 15.71% | 0.96% | 15.07% | 72.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:2784
Alfresa Holdings
2,377.50
289.31
13.85%
JP:7459
Medipal Holdings
2,781.50
438.88
18.73%
JP:9989
Sundrug Co
3,781.00
-778.44
-17.07%
JP:7649
Sugi Holdings Co
3,199.00
264.58
9.02%
JP:9987
Suzuken Co
5,562.00
569.53
11.41%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,709.00
431.25
13.16%
Alfresa Holdings Corporate Events
Alfresa Books ¥15.4 Billion Extraordinary Gain From Sale of Investment Securities
Feb 10, 2026
Alfresa Holdings is a leading player in Japan’s healthcare industry, operating across ethical and OTC pharmaceutical wholesaling, pharmaceutical manufacturing, dispensing pharmacies, and regenerative medicine-related businesses. The Tokyo St...
Alfresa Lifts Earnings, Keeps Guidance and Raises Dividend Despite Margin Pressure
Feb 10, 2026
Alfresa Holdings reported consolidated net sales of ¥2.36 trillion for the nine months ended December 31, 2025, up 4.5% year on year, while operating and ordinary profit declined slightly, but profit attributable to owners of parent jumped 24...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.